New Patients (patients not yet prescribed)

Require informed consent to every patient of the risks and dangers of benzodiazepine/Z-drug use past the recommended 2-4 weeks.
Adhere to the existing guidelines: short-term prescriptions (2-4 weeks only) in minimal dosage
Learn existing non-drug treatments for anxiety and insomnia
Educate doctors, other prescribers, and healthcare workers about the potential dangers of benzodiazepines and Z-drugs

Long-Term Patients (already physically dependent)

Educate the medical community about slow, safer tapering protocols, where the patient (not the prescriber) is in control of the rate/speed, to discontinue the drugs (if the patient desires). Always inform the patient of risks of remaining physically dependent on a benzodiazepine and the risks of cessation.
Funding for benzodiazepine-harm research, patient support groups and dedicated withdrawal clinics.

FDA box or other heightened warnings on the drugs themselves or within the drug literature/patient handout that accompanies the drug prescription. (FDA Announced in September, 2020)
Research into the long-term effects of benzodiazepines.
Greater transparency about the results of drug company sponsored trials.
Continued and persistent pressure (through activism, awareness, lobbying, grassroots efforts) on government health authorities and the public.
In some cases, filing a complaint about negligent medical providers to the State Medical Board (or other prescriber regulatory agencies, depending on location) may be in order, as may the pursuit of litigation and exposing any settlements publicly. This includes cases where inappropriate or abrupt withdrawal has resulted in a severe withdrawal syndrome. Avoiding formal complaints and litigation can be a significant motivator for providers to get quickly educated.